[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100638746":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":19,"locations":10,"responsibleParty":30,"collaborators":10,"id":34,"slug":35,"hasResults":36,"nctId":37,"briefTitle":38,"officialTitle":39,"acronym":40,"eligibilityCriteria":41,"healthyVolunteers":36,"sex":42,"minAge":43,"maxAge":44,"enrollmentInfo":45,"targetDuration":10,"studyType":48,"phases":10,"briefSummary":49,"conditions":50,"keywords":52,"overallStatus":54,"whyStopped":10,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":10},{"fullName":5,"class":6},"Central Hospital, Nancy, France","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients referred for bone scintigraphy for suspected ATTR-CA",null,"Patients referred for bone scintigraphy for suspected ATTR-CA underwent a fast cardiac CZT-SPECT acquisition followed by standard whole-body planar imaging three or four hours after 99mTc-HMDP injection",[13],"Other: bone scintigraphy",[15],{"type":6,"name":16,"description":17,"armGroupLabels":18,"otherNames":10},"bone scintigraphy","Fast CZT camera bone scintigraphy and bone scintigraphy with conventional camera (standard care)",[9],[20,26],{"name":21,"role":22,"phone":23,"phoneExt":24,"email":25},"Pierre-Yves MARIE, MD,PhD","CONTACT","0383153909","+33","py.marie@chru-nancy.fr",{"name":27,"role":22,"phone":28,"phoneExt":24,"email":29},"Véronique ROCH, MSc","0383154276","v.roch@chru-nancy.fr",{"type":31,"investigatorFullName":32,"investigatorTitle":33,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Pierre Yves MARIE","Prinicipal Investigator","100638746","fast-cardiac-bone-spect-czt-in-transthyretin-cardiac-amyloidosis-100638746",false,"NCT07605741","Fast Cardiac Bone SPECT-CZT in Transthyretin Cardiac Amyloidosis","Fast Cardiac Bone 360° SPECT-CZT Accurately Reproduces Planar Perugini ≥ 2 Classification With High Reproducibility in Transthyretin Cardiac Amyloidosis","PeakAmyL","Inclusion Criteria:\n\n* Patients who were routinely referred for bone scintigraphy for suspected transthyretin cardiac amyloidosis (ATTR-CA) between April 2024 and April 2025.\n\nExclusion Criteria:\n\n* Patients who object to the use of their data","ALL","18 Years","95 Years",{"count":46,"type":47},200,"ESTIMATED","OBSERVATIONAL","Transthyretin cardiac amyloidosis (ATTR-CA) is traditionally diagnosed using planar bone scintigraphy with a Perugini visual score ≥ 2. Fast cardiac CZT-SPECT will be evaluated for its ability to reproduce this classification and provide reproducible quantitative myocardial uptake metrics.",[51],"Cardiac Amyloidosis",[53],"Cardiac amyloidosis, Bone scans, CZT, SPECT-CT, Perugini","NOT_YET_RECRUITING","2026-05-18",{"date":57,"type":58},"2026-05-26","ACTUAL",{"date":60,"type":47},"2026-05-30",{"date":62,"type":47},"2026-07-30",{"name":5,"class":6}]